>£2m contract extension win in Huntington's disease

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has executed a c. £2m contract to provide additional imaging services that will support a pivotal Huntington's disease (HD) study. This builds on the Company's existing contract to support our 'top-20' pharma client's Phase III study in HD.

This contract does not have significant impact on management's expectations of performance for the coming year, but will contribute to the Company's already strong order book for next year.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are delighted that our client has chosen to expand our partnership to support its study extension for Huntington's disease. This decision validates our technology and endorses the service provided as we help our clients throughout the trial pathway. IXICO is proud to support the development of treatments for this devastating rare disease."

For further information please contact:


+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer


Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0)20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)


Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or IXICO@walbrookpr.com

Paul McManus / Lianne Cawthorne /


Alice Woodings

Date: 29/09/2020